Assay Development and Screening
Aida Clarisa Salado, PhD
General Manager
INNOPROT
Derio, Pais Vasco, Spain
Increasing evidences aim the aggregation of a-synuclein (aS) as one of the critical factor in the development of Parkinson´s disease in human brain. Some studies suggest that this aggregation may be triggered by factors linked to apoptosis like the protein kinases inhibitor staurosporine2.
In this work, we have developed a fluorescence cell-based assay for High Content Screening (HCS) to find compounds that can prevent the staurosporine-induced aggregation of a-synuclein in human neuroblastoma SH-SY5Y cell line.
SLAS Events